within Pharmacolibrary.Drugs.ATC.N;

model N02CA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.02,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008400000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0031166666666666665,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.0091,
    k12             = 1.05,
    k21             = 1.05
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ergotamine is an ergot alkaloid used for the acute treatment of migraine attacks and cluster headaches. It is a vasoconstrictor and acts by stimulating alpha-adrenergic and serotonergic (5-HT1) receptors. Use of ergotamine has declined due to the availability of triptans and its side effect profile. It is currently approved in some countries but less commonly used.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both sexes, following a single oral dose.</p><h4>References</h4><ol><li><p>Perrin, VL (1985). Clinical pharmacokinetics of ergotamine in migraine and cluster headache. <i>Clinical pharmacokinetics</i> 10(4) 334–352. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198510040-00004&quot;>10.2165/00003088-198510040-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3899452/&quot;>https://pubmed.ncbi.nlm.nih.gov/3899452</a></p></li><li><p>Sanders, SW, et al., &amp; Jaeger, H (1986). Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. <i>European journal of clinical pharmacology</i> 30(3) 331–334. DOI:<a href=&quot;https://doi.org/10.1007/BF00541538&quot;>10.1007/BF00541538</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3732370/&quot;>https://pubmed.ncbi.nlm.nih.gov/3732370</a></p></li><li><p>Diener, HC (2005). Eletriptan in migraine. <i>Expert review of neurotherapeutics</i> 5(1) 43–53. DOI:<a href=&quot;https://doi.org/10.1586/14737175.5.1.43&quot;>10.1586/14737175.5.1.43</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15853473/&quot;>https://pubmed.ncbi.nlm.nih.gov/15853473</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CA02;
